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Objective: Men affected by incurable prostate cancer is expected to increase worldwide.  Research is 
needed to enable men to share their experiences of unmet supportive care needs in current care 
delivery. We aimed to identify the most frequently reported domains of unmet supportive care needs, 
levels of anxiety, depression, distress, health-related quality of life, and to identify any perceived 
barriers to receiving supportive care.   
Data Sources: Men diagnosed with prostate cancer who had received a minimum of 6 months of ADT 
were recruited into a cross-sectional study.    Participants completed standardised questionnaires, 
clinical and demographic data was also collected. 
 Conclusion: 272 patients were invited, and 102 participated.  No statistically significant differences 
were found between participants scores from Australia and UK in relation to anxiety and depression, 
exercise, HRQoL or distress scores.  Perceived barriers in service delivery related to information 
provision and difficulties in the navigation of complex care systems.  
Implications for Nursing Practice: Men affected by prostate cancer receiving ADT reported unmet 
supportive care needs, specifically related to sexual, informational and psychological aspects of care.  
Mapping future trajectories of needs and identifying men at high risk can significantly improve timely 
and tailored interventions.   
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Prostate cancer remains the most common cancer among older men, and is the second leading 
malignancy in the western world 1. The mainstay treatment for advanced prostate cancer disease aims 
to reduce systemic testosterone levels, which can be achieved surgically or by chemical castration, 
known as androgen deprivation therapy (ADT) 2.  However, newer therapies for advanced prostate 
cancer have improved survival rates 3-7 and therefore, many more men are requiring on-going 
supportive care.   
Men affected by advanced prostate cancer have an incurable disease, and men can report a range of 
unmet supportive care needs in routine service delivery 8-10.  Moreover, men can experience a range 
of symptoms that can negatively affect their quality of life and can increase the need for supportive 
care interventions 11,12.  Side effects which have been identified as particularly challenging include: (i) 
body feminization (gynecomastia, hot flushes, loss of muscle mass, genital shrinkage); (ii) changes in 
sexual function and lack of libido; (iii) relationship changes; (iv) cognitive and affective symptoms; and 
(v) fatigue, sleep disturbance, and depression 8,13,14. 
Supportive care is a person-centred approach to the provision of the necessary services for those living 
with or affected by prostate cancer to meet their informational, spiritual, emotional, social, or physical 
needs during diagnosis, treatment, or follow-up phases including issues of health promotion and 
prevention, survivorship, palliation and bereavement 15. The need to improve supportive and palliative 
care for adults with incurable cancer is recognised internationally 16 to increase patient satisfaction 
with demonstrated cost-effectiveness.  Additional research is needed to enable men to share their 
experiences to understand why unmet supportive care needs are persistent in current care delivery 
15,17.  This study aims to investigate the unmet supportive care needs experienced by men affected by 
advanced prostate cancer in two countries with similar healthcare systems.  Gaining more evidence in 





for models of advanced prostate cancer care.  Therefore, this study aimed to address the following 
research questions:   
1) What are the most frequently reported domains of unmet supportive care needs by men 
affected by advanced prostate cancer receiving ADT, and are they different between 
countries? 
2) What are the self-reported levels of anxiety, depression, health-related quality of life and 
distress experienced by men affected by advanced prostate cancer receiving ADT? 
3) What are men’s experiences of the barriers to receiving appropriate supportive care? 
Methods 
Design 
An observational, cross-sectional quantitative design was conducted. 
Conceptual framework 
The conceptual framework for this study was informed by the prostate cancer model of consultation 
18 to identify the standardised questionnaire instruments to be used in this study to address the 
research questions. 
Setting 
After ethical approval was granted (UK: 16/WS/0211 and Australia: 16/MH/12) this study recruited 
patients from the UK and Australia.  Patients were recruited in United Kingdom, National Health 
Service (NHS) Tayside which serves a predominantly Caucasian rural and urban population of more 
than 405,721 and is served by 75 general practices and single tertiary urological cancers services.  
Patients were recruited in Victoria, Australia from a range of private practices associated with Epworth 
Healthcare Richmond and the public men’s health clinic at the Australian Prostate Centre. These 
locations offered a good cross-section of this patient population with both public and privately insured 





men affected by advanced prostate cancer in Australia and the UK because both countries are 
developed and have access to a publicly funded healthcare system. 
 
Participants 
Inclusion: Patients were recruited into the study if they met the following inclusion criteria:  
a) diagnosed with locally advanced or metastatic prostate cancer who are currently undergoing 
treatment with ADT,  
b) commenced ADT at least 6 months prior to study enrolment,  
c) able to read and write English or agreeable to access translation support and,  
d) provided informed consent by returning the questionnaire pack where consent had been explained 
in the accompanying letter.   
Exclusion criteria 
a) patients undergoing concomitant or previous radiotherapy or chemotherapy for their 
prostate cancer. 
Recruitment 
All eligible patients were identified by clinicians at the study sites. Members of the healthcare team 
were responsible for sending a letter of invitation and recruitment packs.  The recruitment packs 
contained the following: participant information sheet, questionnaire pack and a stamped, self-
addressed return envelope.  No further follow-up contact was made with patients who did not return 
their questionnaires. Informed consent was implied on the bases of a completed questionnaire. 
Variables 
Clinical and demographic data was collected from the questionnaires.  The information collected 
included the following:  
• Demographic variables: age, marital status, sexual orientation, ethnicity, level of education, 





• Clinical variables: time since diagnosis, date of commencement of ADT, and whether ADT was 
intermittent or continuous therapy. 
Patient reported outcome measures 
Supportive Care Needs Survey (SCNS-SF34) and the prostate-specific module  
The Supportive Care Needs Survey is a validated instrument assessing perceived need in the domains 
of psychological needs, health system and information needs, physical and daily living needs, patient 
care and support, sexuality, need for access to services and resources 19.   A short form (34 items) of 
this survey (SCNS-SF34) has been validated for use in men with prostate cancer 20.   
Expanded Prostate Cancer Index Composite short form (EPIC-26) 
The EPIC-26 is a self-report 26-item to measure of health-related quality of life among prostate cancer 
patients 21, that has been shown to have good reliability and validity.  EPIC items have Likert scale 
response options with higher scores representing better quality of life. 
Godin Leisure-Time Exercise Questionnaire  
The Godin Leisure-Time Exercise Questionnaire 22 is a 4-item self-report measure of physical activity 
engagement. It has been shown to have good reliability and validity in measuring engagement in 
physical activity.  
The Distress Thermometer (DT)  
The DT is a widely used 1-item visual analogue scale which measures self-reported distress. This 
measure has been validated for use with men with prostate cancer 23.  A score of 4 or above indicates 







General Anxiety Disorder-7 (GAD-7) 
The GAD-7 was used to assess anxiety 24. The GAD-7 was developed from the DSM-IV-TR (Diagnostic 
and Statistical Manual of Mental Disorders, fourth edition, Text Revision) 25 diagnostic criteria for 
Generalised Anxiety Disorder. The GAD-7 has widely demonstrated reliability and validity in general 
and primary care patient populations 26. It has also been recommended for use in screening and 
assessment in adult cancer patient populations 27. 
Patient Health Questionnaire (PHQ-9)  
The PHQ-9 28 was developed from the diagnostic criteria for Major Depressive Disorder (MDD) from 
the DSM-IV-TR 25.  This measure was used to assess depression. The PHQ-9 has been shown to possess 
good validity for patients with mild, moderate and severe depression. 
Supportive Care Services Survey 
Patients were asked to identify the medical and allied health practitioners involved in their care and 
any supportive services they accessed since they commenced ADT. They were asked to identify any 
supportive care services they would like to have access to, but have been unable to do so, and to select 
reasons why they have not been able to access these. Barriers to supportive care services that were 
listed in the questionnaire was informed 29. 
Statistical methods 
Prior to the analysis, variables were examined for accuracy of data entry, missing values and the 
assumptions of the proposed analysis. This verification was done through traditional exploratory 
analysis 30. Normality distributions of the variables were checked by statistical and graphical methods. 
Skewness and Kurtosis significance values were assessed using the Kolmogorov-Smirnov (K-S) test and 
a histogram was plotted for each variable. To address the research questions, statistical analysis was 






A total of 105 patients from United Kingdom and a total of 167 patients from Australia were invited 
to participate.  A total of 102 (n=41 UK, n=61 Australia) men diagnosed with locally advanced or 
metastatic prostate cancer consented to take part in the study (37.5% response rate). The reasons for 
non-participation in this study will remain unknown due to the cross-sectional postal survey design 
and ethical restrictions placed on collecting clinical and demographic data of the non-participants.   
Most of the study participants were >70 years of age (80.4%), married (76.5%), retired (77.5%), and 
Caucasian (86.3%), see Table 1 for clinical and demographic characteristics of the study participants.    
We observed a statistically significant difference in age between the study participants in UK median 
80.9 (66-91) years, and Australia 76.4 (61-96) years, p=.034 respectively.   Statistically significant 
differences were also observed in time since diagnosis between the UK (median 3 [1-11] years) and 
Australia (10 [2-30] years), p=.000, and the duration of ADT between the countries UK (1.6 [0-9] years) 
and Australia (3.2 [0-19] years), p=.004.   
Men experienced a range of unmet supportive care needs with the highest scores relating to 
informational, psychological and sexual needs, see Table 2. No statistically significant differences in 
unmet needs between the participants from UK or Australia were observed in relation to the physical 
and daily, patient care and support, sexuality, psychological or informational needs, see Table 3. 
Moreover, no statistically significant differences were found between scores from Australia and UK in 
relation to anxiety and depression scores, exercise scores, and HRQoL domains. The only exception 
was on the matter of urinary incontinence, see Table 3. 
Using the PHQ-9 cut-off scores of 0-4 (no depression), 5-9 (mild), 10-14 (moderate) 15-19 (moderately 
severe) and 20-27 (severe) 28 we observed (no depression; n=72, 80 %), (mild; n=9, 10%), (moderate; 
n=5, 5.5 %), (moderately severe; n=3, 3.3%), and (severe; n=1, 1.2%).  Similarly using the same scoring 





(moderately severe; n=3, 3.1%) and (severe; n=1, 1.1%).  We used the cut of score of 4≥ on the distress 
thermometer 23 (n=14, 14.2%) were at risk of experiencing clinically significant levels of distress. 
Barriers to accessing health care 
Overall most of the participants in the study did not perceive barriers to accessing supportive care in 
the UK and Australia. However, patients perceived barriers to accessing supportive care services due 
to a lack of information, see Table 4.    Patients identified gaps in their experience of information 
provision in service delivery, with a focus on the consequences of ADT and how to self-manage their 
associated side-effects.  Other patients highlighted a lack of understanding about how to navigate the 
complex care system to access services which they may have required.  Patients also shared positive 
experiences of supportive care delivery in the UK and Australia which was related to having good 
access to specialist nurses. 
Discussion 
To our knowledge, this is the first bi-country study conducted to explore the unmet supportive care 
needs and barriers to engagement in support services for men living with locally advanced or 
metastatic prostate cancer receiving androgen deprivation therapy.  The primary focus of this study 
was to gain more information about the experience of unmet supportive care in men affected by 
advanced prostate cancer.  Interestingly, we did not observe any statistically significant differences in 
the reported domains of unmet needs between participants in the UK and Australia.  These results are 
in keeping with existing studies that have persistently reported unmet supportive care needs in 
developed countries, such as Canada 9, Australia 10, and the UK  8,12 for men affected by advanced 
prostate cancer.    Thus indicating that key areas of supportive care domains remain suboptimal for 
some men.   To date, most studies that have explored unmet needs of men affected by locally 
advanced or metastatic prostate cancer receiving ADT have been conducted within one state or 





of the geographical location in which existing studies have be conducted, participants commonly 
report areas of unmet needs related to informational, psychological and sexual needs, this 
underscores that further global intervention studies are required to address these inherent gaps in 
care provision for men. 
Generally, facilitating access is concerned with helping people to command appropriate healthcare 
resources to persevere or improve patient’s health 31.  We considered the barriers of accessing support 
in the context of differing patient perspectives which included the patient’s health needs, and material 
and cultural needs of a diverse group across two countries.   Most men in this study did not reported 
any perceived barriers to accessing support services.  However, of the men who did perceive barriers, 
these were related to a lack of information provision, particularly around treatment, self-management 
and patient navigation in the healthcare system.  These findings are consistent with those published 
elsewhere 12,32 in that men may require multimodal interventions and active encouragement to 
overcome barriers and access additional support for rehabilitation related to sexual and emotional 
issues. 
A clinically important finding was that approximately twenty percent of the study sample were at risk 
of anxiety and depression.  Our results report similar prevalence rates to those published in a meta-
analysis on the prevalence rates on anxiety and depression among men affected by prostate cancer 
33.  Furthermore, around fifteen percent were at risk of experiencing significant levels of distress.  This 
emphasises that despite routine clinical follow-up patients are not receiving the timely and tailored 
person-centred interventions required.  Patient reported outcome measures (PROMs) were originally 
developed for research use, but as proactive clinicians have recognised the benefits of PROMs they 
have gained additional use in routine clinical practice 34.  Through the routine use of PROMs in clinical 
practice this may help clinicians to appropriately risk stratify patients who need tailored interventions.  
Currently, we do not have a universally agreed PROM for routine use in prostate cancer care.  We 





to avoid the concurrent disconnect and when interpreting trial results and the associated difficulties 
in translating them into routine clinical practice.   
A further clinically relevant finding was in relation to the time since diagnosis of men diagnosed with 
prostate cancer and the duration of ADT between the men in the UK and Australia. Despite this 
observed difference between both study groups we did not observe any statistically significant 
difference in anxiety, depression, distress or quality of life scores, with the exception for the urinary 
incontinence domain.   
Strengths/Limitations 
There were several limitations worthy of comment.  The number of participants recruited into the 
study were lower than expected but due to ethical confinements, we were unable to explore 
recruitment bias with a range of clinical or demographic variables.  However, this is one of the largest 
studies to date to explore elderly men’s experience of unmet needs, and this was a strength.  
Approximately 40% of the participants were over 80 years of age, and noteworthy the oldest 
participant was 97 years old.  The participants were biased in favour of Caucasian, married, English-
speaking and retired men which limits the generalisability of this study.   Further research is urgently 
needed to explore areas of unmet needs with different demographic groups, other than those 
represented in our study, including typically hard to reach groups, such as Aboriginal and Torres Strait 
islander patient populations.   
This was a cross-sectional study that had good representation of patients who were diagnosed within 
one year to 30 years of receiving ADT, but these results only provided a snapshot of the experience of 
unmet needs at one given time point.  Moreover, the recruitment pathways of the men who took part 
in this study may not be representative of those in other geographical areas in both respective 
countries.  Further prospective longitudinal research is required to understand how needs change over 





predict domains of unmet needs to enable clinicians to identify those patients at higher risk.  Relatedly, 
dyadic quantitative, qualitative studies and complex interventions could enhance our understanding 
of the relationship dynamics and manifestations of interrelated needs.   
Conclusion 
Men affected by advanced prostate cancer receiving ADT report unmet supportive care needs related 
to sexual, informational and psychological aspects of care.  Mapping the trajectories of needs and 
identifying men at higher risk can significantly improve our ability to offer more timely and tailored 
interventions.  Future research is needed to explore whether demographic and clinical factors may 
moderate or mediate the manifestation of needs for men affected by prostate cancer receiving ADT 
over time.   Meanwhile, clinicians are encouraged to use these findings in their everyday clinical 
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Table 1. Distribution of clinical and demographic characteristics. 
Characteristics N% 
Country response   
United Kingdom 41 40.2 
Australia 61 59.8 
Age   
61–70 years 20 19.6 
71–80 years 38 37.3 
81–90 years 35 34.3 
90–100 years 9 8.8 
Marital status   
Single/never married 2 2.0 
Divorced or separated 4 3.9 
Married 78 76.5 
Living with partner 3 2.9 
Widowed 15 14.7 
Sexual orientation   
Heterosexual 94 92.2 
Gay 0 0 
Bisexual 1 1.0 
Other 3 2.9 
Missing data 4 3.9 
Race   
White 88 86.3 
Indigenous 1 1.0 
Asian 3 2.9 
Other 5 4.9 
Missing data 5 4.9 
Highest qualification   
School education only 44 43.1 
TAFE qualification 16 15.7 
Bachelor degree 11 10.8 
Honours degree 2 2.0 
Postgraduate certificate 2 2.0 
Postgraduate diploma 2 2.0 
Master's degree 4 3.9 
Master's degree by research 1 1.0 
Doctorate 4 3.9 
Other 15 14.7 





Private health insurance   
Yes 52 51.0 
No 49 48.0 
Missing data 1 1.0 
Employment   
Working full-time 10 9.8 
Working part-time 7 6.9 
Unemployed 4 3.9 
Retired 79 77.5 
Missing 2 2.0 
Time since diagnosis   
0–1 years 7 6.9 
2–5 years 45 44.1 
6–10 years 20 19.6 
11–20 years 24 23.5 
21–30 years 3 2.9 
Missing data 3 2.9 
Duration of ADT*   
<1 year 3 2.9 
1–2 years 41 40.2 
3–5 years 33 32.4 
6–10 years 13 12.7 
11–15 years 4 3.9 
16–20 years 1 1.0 
Missing data 7 6.9 
Continuous ADT   
Yes 72 70.6 
No 12 11.8 
Missing 18 17.6 











Table 2. Distributions of unmet supportive care needs (SCNS34). 
Unmet Need* In the 
last month, what was 









I did need 
help with 




the time N 
(%) 
Low unmet 




help N (%) 
Moderate 
unmet need. 
I had some 
need for 
additional 
help N (%) 
High unmet 




help N (%) 
Pain 77 (77) 8 (8) 7 (7) 6 (6) 2 (2) 
Lack of 
energy/tiredness 43 (43.4) 25 (25.3) 10 (10.1) 15 (15.2) 6 (6.1) 
Feeling unwell a lot 
of the time 73 (74.5) 9 (9.2) 11 (11.2) 3 (3.1) 2 (2) 
Work around the 
home 62 (63.9) 16 (16.5) 14 (14.4) 3 (3.1) 2 (1.9) 
Not being able to do 
the things that you 
used to do 
41 (41.8) 23 (23.5) 19 (19.4) 9 (9.2) 6 (6.1) 
Anxiety 61 (61.6) 16 (16.2) 18 (17.5) 3 (2.9) 1 (1) 
Feeling down or 
depressed 64 (65.3) 14 (14.3) 13 (13.3) 5 (5.1) 2 (2.0) 
Feelings of sadness 64 (64.6) 15 (15.2) 15 (15.2) 4 (4.0) 1 (1.0) 
Fear about the 
cancer spreading 36 (36.4) 35 (35.4) 19 (19.2) 7 (7.0) 2 (2.0) 
Worry that the 
results of treatment 
are beyond your 
control 
53 (53.5) 21 (21.2) 18 (18.2) 5 (5.1) 2 (2.0) 
Uncertainty about 
the future 46 (46.5) 23 (23.2) 21 (21.2) 6 (6.1) 3 (3.0) 
Learning to feel in 
control of your 
situation 
53 (53.5) 22 (22.2) 20 (20.3) 2 (2.0) 2 (2.0) 
Keeping a positive 
outlook 59 (60.2) 24 (24.5) 11 (11.2) 2 (2.0) 2 (2.0) 
Feelings about death 
and dying 59 (59.6) 21 (21.2) 14 (14.1) 4 (4.0) 1 (1.0) 
Changes in sexual 
feelings 61 (62.2) 16 (16.3) 10 (10.2) 7 (7.1) 4 (4.1) 
Changes in sexual 
relationships 64 (65.3) 15 (15.3) 8 (8.2) 6 (6.1) 5 (5.1) 
Concerns about the 
worries of those close 
to you 





Unmet Need* In the 
last month, what was 









I did need 
help with 




the time N 
(%) 
Low unmet 




help N (%) 
Moderate 
unmet need. 
I had some 
need for 
additional 
help N (%) 
High unmet 




help N (%) 
More choice about 
which cancer 
specialist you see 
65 (65.7) 22 (22.2) 8 (8.1) 3 (3.0) 1 (1.0) 
More choice about 
which hospital you 
attend 
63 (64.9) 25 (25.8) 5 (5.2) 1 (1.0) 3 (3.1) 
Reassurance by 
medical staff that the 
way you feel is 
normal 
59 (59.6) 31 (31.3) 8 (8.1) 1 (1.0) 0 (0) 
Hospital staff 
attending promptly 
to your physical 
needs 




to, your feelings and 
emotional needs 
66 (66.7) 28 (28.3) 4 (4.0) 2 (1.0) 0 (0) 
Being given written 
information about 
the important 
aspects of your care 




about managing your 
illness and side 
effects at home 
67 (67.7) 23 (23.2) 3 (3.0) 5 (5.1) 1 (1.0) 
Being given 
explanations for 
those tests for which 
you would like 
explanations 
57 (58.2) 30 (30.6) 5 (5.1) 4 (4.1) 2 (2.0) 
Being adequately 
informed about the 
benefits and side 
effects of treatment 
before you choose to 
have them 





Unmet Need* In the 
last month, what was 









I did need 
help with 




the time N 
(%) 
Low unmet 




help N (%) 
Moderate 
unmet need. 
I had some 
need for 
additional 
help N (%) 
High unmet 




help N (%) 
Being informed 
about test results as 
soon as feasible 
43 (43.9) 41 (41.8) 8 (8.2) 2 (2.0) 4 (4.1) 
Being informed 
about cancer that is 
under control or 
diminishing 
47 (48) 39 (39.8) 3 (3.1) 6 (6.1) 3 (3.1) 
Being informed 
about the things that 
you can do to get well 
41 (42.3) 38 (39.2) 8 (8.2) 5 (5.2) 5 (5.2) 
Having access to 
professional 
counselling 




67 (68.4) 18 (18.4) 7 (7.1) 3 (3.1) 3 (3.1) 
Being treated like a 
person not just 
another case 
54 (55.7) 35 (36.1) 5 (5.2) 0 (0) 3 (3.1) 
Being treated in a 
hospital or clinic that 
is as physically 
pleasant as possible 
49 (50.0) 43 (43.9) 3 (3.1) 0 (0) 3 (3.1) 
Having one member 
of hospital staff with 
whom you can talk to 
52 (53.1) 35 (35.7) 7 (7.1) 0 (0) 4 (4.1) 
Distributions of Unmet Supportive Care Needs (prostate cancer supplement) 
Urinary incontinence 67 (68.4) 17 (17.3) 11 (11.2) 1 (1.0) 2 (2.0) 
Difficulties in passing 
urine 79 (79.8) 15 (15.2) 3 (3.0) 1 (1.0) 1 (1.0) 
Hot flushes 57 (57.0) 23 (23.0) 8 (8.0) 10 (10.0) 2 (2.0) 
Feeling as if you are 
going through a 
change of life like 
women do 
65 (65.7) 15 (15.2) 10 (10.1) 8 (8.1) 1 (1.0) 
Feeling like you've 
lost part of your 
manhood 





Unmet Need* In the 
last month, what was 









I did need 
help with 




the time N 
(%) 
Low unmet 




help N (%) 
Moderate 
unmet need. 
I had some 
need for 
additional 
help N (%) 
High unmet 




help N (%) 
Feeling that what 
you say is not taken 
seriously by others 
70 (70.0) 21 (21.0) 5 (5.0) 4 (4.0) 0 (0) 
Feeling like you have 
lost the ability to be 
aggressive 
71 (71.7) 21 (21.2) 6 (6.1) 1 (1.0) 0 (0) 
Problems with your 
bowel habits 62 (62.0) 21 (21.0) 12 (12.0) 5 (5.0) 0 (0) 
 
 
Table 3. Distribution of scores between study participants in Australia and UK on 
standardised questionnaires. 
Domain Australia (n=61) UK (n-41) P value 
EPIC    
Urinary incontinence 79.2 (0-100) 95.8 (54.2-100) .013 
Urinary irritative/obstructive 93.7 (43.7-100) 93.7 (50-100) .393 
bowel function 100 (25-100) 95.8 (58.3-100) .526 
Sexual function 16.6 (0-40.3) 16.6 (0.83.3) .394 
Hormone function 75 (10-100) 80 (35-100) .286 
SCNS    
Physical and daily needs 90 (10-100) 90 (25-100) .636 
Patient care and support 91.1 (50-100) 90 (45-100) .414 
Sexuality needs 91 (0-100) 88 (8.3-100) .292 
Psychological needs 87.5 (15-100) 82.5 (32.5-100) .488 
Health system information needs 84.5 (45.4-100) 90 (25-100) .309 
PHQ-9    
Depression 2.0 (0-22) 2.0 (0-16) .654 
GAD-7    
Anxiety 1.0 (0-16) 0.0 (0.20) .096 
Distress Thermometer 1.0 (0-10) 0.0 (0-7) .053 











Inadequate health insurance 1 5 
Lack of co-ordination of care among service provides 2 2 
Too much time waiting for an appointment 4 1 
Inability to pay for treatment related expenses 1 2 
Transportation problems 1 1 
Lack of child or elderly care 2 1 
Language barriers 0 1 
Cultural barrier 0 1 
Anxiety 0 1 
Depression 1 1 
Worries that work wages will be lost 1 1 
Lack of information 1 5 
Ignoring physical pain or symptoms 1 1 
Lack of information about where to find appropriate care 0 3 
Other health problems 1 1 
Too busy with other commitments 0 2 
Reluctant to participate in health care decisions 3 2 
Patients open qualitative comments   
Facilitators and positive experiences  Australia 
Each individual, in the services I've used, has shown nothing but 
excellence in their efforts on my behalf. I congratulate them and can't 
thank them enough. 
UK  
All therapies and advice have been of very great help to me. UK  
I have been to Maggie's (Cancer Care Centre) and found the info I 
received to be very helpful. Plus the fact the nurse who dealt with me 
was extremely proficient. 
 Australia 
EPC (Epworth Prostate Centre) provides a wonderful forum for 
discussion of all issues related to ADT. 
 Australia 
My urologist, nurse and GP have all been excellent. I am in contact 
with the nurses if I have any queries and receive immediate replies. UK 
 
Coping strategies   
No barriers sought. I have conquered my life and activities as I have 
been in the past and am not aware of any effects of hormone therapy 
apart from inability to produce an erection fully or at all. 
UK  
The first 6 months were difficult coming to terms with the illness, etc. 
A TURP operation in the late 2014 made a huge difference and since 
then I have tried to continue my normal life as much as possible, I 
take lots of exercise and remain positive. Should I consider I need 










I have an appointment with sexual therapy this month. I am very 
grateful for the quality of care and attention I have experienced. 
Barriers to supportive care UK  
Lack of information  Australia 
I am surprised that having finished taking my tablets for 28 days early 
July I have no further contact with medical services until September, 
but I figure they know what they are doing. 
 Australia 
A simple information sheet with services and access points provided at 
time of treatment commenced (or before) would be highly beneficial. 
 Australia 
Information needed about ALL side effects of ADT: impact on 
incontinence & nervous system was lacking 
 Australia 
Like to know what hormone therapy is? UK  
I discussed all issues with my GP he felt further referrals unnecessary  Australia 
Low energy & tiredness need to be addressed Lack of knowledge of 
available services I gave up driving on my 88th birthday and reaching 
the Hospital is difficult but not excessive. I fractured my right femur 
in a cycling accident late last year and coupled with vision problems I 
may require transport help in the future. I would appreciate a monthly 
visit by a district nurse, but they consider me too mobile to benefit 
from this service. 
 Australia 
No supportive services have been offered. Do not know what is 
available. Feel isolated. What services? 
  
Abbreviations: ADT, androgen deprivation therapy; GP, general practitioner; TURP, 
transurethral resection of the prostate. 
 
